表紙
市場調査レポート

循環腫瘍細胞(CTC)の診断:技術と世界市場

Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets

発行 BCC Research 商品コード 294447
出版日 ページ情報 英文 237 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.69円で換算しております。
Back to Top
循環腫瘍細胞(CTC)の診断:技術と世界市場 Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets
出版日: 2014年01月29日 ページ情報: 英文 237 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

循環腫瘍細胞(CTC)技術の世界市場は2012年には28億米ドル近い規模に達し、2013年には37億米ドルに達しました。今後同市場はCAGR(複合年間成長率)18.9%の伸び率で、2018年には89億米ドルの規模に達することが見込まれています。

当レポートでは、世界の循環腫瘍細胞(CTC)診断市場について分析し、主要な技術および商業的な側面を取り上げて、市場規模、産業の成長率および市場動向をまとめるとともに、CTC市場における最近の動向を提示し、主要な企業のプロファイルをまとめるなど、概略下記の構成でお届けいたします。

第1章 イントロダクション

  • 調査の目標と目的
  • 調査実施理由
  • 対象読者
  • 調査範囲
  • 調査手法
  • 情報源
  • 著者について
  • 関連レポート
  • BCCオンラインサービス
  • 免責

第2章 サマリー

第3章 循環腫瘍細胞(CTC)

  • 癌幹細胞(CSC)
  • 循環腫瘍細胞:潜在的用途
  • 増殖活動
  • 循環腫瘍細胞上の上皮マーカー遺伝子
  • 循環腫瘍細胞と幹細胞様表現型
  • CTCおよび主腫瘍細胞:比較
  • 転移
  • 癌患者における転移の進行
  • 循環腫瘍細胞の移動
  • 遠隔転移の重要マーカー
  • 検出の課題
  • 循環腫瘍DNAの臨床用途
  • 治療応答の予知因子としての循環腫瘍細胞
  • CTCの測定基準:用途
  • 結論

第4章 癌の発生率

  • 癌発生率の世界的な増加
  • 癌の原因
  • 癌のリスク要因
  • 癌の負荷
  • 早期発見
  • 治療
  • 苦痛緩和治療
  • 世界的な癌の統計
  • 癌の将来
  • 米国における癌の発生率
  • 乳癌
  • 結腸直腸癌
  • 前立腺癌
  • 結論

第5章 技術

  • 循環腫瘍細胞の発見
  • 現在のCTC検出・分離手法
  • 新たな検出技術
  • 癌の予後
  • CTC検出技術:要件
  • 濃縮法
  • 検出法
  • 複合濃縮・検出法
  • 核酸を使った手法
  • 臨床試験
  • サマリー
  • 新興技術

第6章 循環腫瘍細胞と癌診断

  • 診断におけるCTCの利用
  • 前立腺癌における循環腫瘍細胞:ケーススタディー
  • 比較診断におけるCTC
  • 開発段階にある、より新しい技術
  • CTCの分子解析
  • 結論

第7章 臨床試験におけるCTC

  • CTC診断
  • 認可
  • 最近の研究
  • 中国におけるCELLSEARCH
  • 応用
  • 臨床試験へのCTC技術の応用
  • 臨床開発のためのCT技術
  • 標準の提言
  • 予知研究
  • 代理反応バイオマーカーとしてのCTC
  • リアルタイム生体検査法としてのCTC
  • CTCチップ技術とEGFR変異分析
  • CELLSEARCH プラットフォームを使った濃縮後のCTC特性化
  • 最後の所見

第8章 循環腫瘍細胞市場

  • 侵襲性癌
  • 癌生存率
  • 世界の年間腫瘍市場
  • 米国における癌のコスト
  • 乳癌
  • 結腸直腸癌
  • 化学療法市場
  • 現在の癌診断検査
  • 普遍的な腫瘍検査:可能なのか?
  • 癌バイオマーカー検査市場
  • 癌バイオマーカー検査
  • 癌疾患管理
  • パーソナライズ化された癌検査
  • 臨床診断市場
  • 市場の現状
  • 時間軸
  • アジア太平洋固形腫瘍市場
  • 将来および次の段階

第9章 特許

第10章 主要企業のプロファイル

第11章 参考文献

図表

目次
Product Code: PHM153A

The global market for circulating tumor cell (CTC) technology reached nearly $2.8 billion in 2012 and $3.7 billion in 2013. This market is estimated to reach nearly $8.9 billion by 2018, demonstrating a compound annual growth rate (CAGR) of 18.9% for the five-year period, 2013 to 2018.

This report provides:

  • An overview of the global market for cancer diagnostics based on circulating tumor cells, which are used to increase understanding of tumor cell biology and metastatic cancer as a disease.
  • Analyses of global market trends, with data from 2012 and 2013, and projections of compound annual growth rates for the period of 2013 to 2018.
  • Discussion of the advantages and disadvantages of CTC enrichment techniques.
  • Estimations of cancer incidence, cancer deaths, new cases by type in the United States, and breast cancer statistics and facts.
  • Examination of growth opportunities and drivers in the CTC market and recent breakthroughs in research, along with a patent analysis.

STUDY GOALS AND OBJECTIVES

This report, PHM153A - Circulating Tumor Cell (CTC) Diagnostic: Technologies and Global Markets, gives market insight on monitoring tests used for cancer prognoses. The market is analyzed by cancer type: prostate, breast and colorectal. This report analyzes the circulating tumor cells market, including technologies as well as commercial perspective and describes the overall market size, industry growth rate and market trends. It gives a summary of the recent developments in the CTC market and includes detailed profiles of key players.

The report's focus is on circulating tumor cell testing and monitoring methods. The report also includes an overview on cancer, diagnostic strategies and treatment technologies. Important trends in the field of cancer research and development have been reviewed in this report, and sales forecasts by treatment and screening categories are provided from 2013 through 2018. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the circulating tumor cell market.

REASONS FOR DOING THIS STUDY

This study was conducted to provide detailed information regarding new developments, testing and treatment options for cancer. There is an increasing need for new and innovative technologies. This industry is experiencing growth; the use of new diagnostic technologies for cancer has increased in the past few years.

This BCC Research study will increase the awareness of current and emerging technologies and diagnostics for cancer, especially prostate, breast and colorectal cancer.

SCOPE OF THE STUDY

The scope of this study is clinical testing, prognostic and monitoring markets for CTCs in cancer. The report also includes the clinical segment, currently approved CTC tests and their markets, the regulatory environment, current technologies, new technologies, cancer incidence, market projections and market share along with the latest trends and new developments in this area. This report does not include the segment's research market including reagents, or any accessories used for CTC isolation or studies. The research segment of the market includes numerous competitors with different capabilities, developing and commercializing products such as CTC isolation devices and protocols, CTC characterization reagents, assay and instrumentation, and various identification technologies based on cell imaging. These market players include specialized or research-based companies that contribute considerably to the technological advancements in the field of CTC technologies. The data collected for the report is focused on breast, prostate and colorectal cancers for which clinical data and tests are available currently on the market. CTCs in other cancers are being researched and some are in clinical trials; these are not included within the scope of this report.

ABOUT THE AUTHOR

Usha Nagavarapu, PhD, is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification including investigational new drug (IND)-enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. Usha has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • INTENDED AUDIENCE
  • SCOPE OF THE STUDY
  • METHODOLOGY
  • INFORMATION SOURCES
  • ABOUT THE AUTHOR
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • SUMMARY TABLE: GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING TUMOR CELL TECHNOLOGY, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING TUMOR CELL TECHNOLOGY, 2012-2018 ($ MILLIONS)

CHAPTER 3 - CIRCULATING TUMOR CELLS

  • CANCER
    • RECENT ADVANCES IN TECHNOLOGY
    • INVASIVE POWER
  • CIRCULATING TUMOR CELL
    • PHENOTYPIC CHARACTERISTICS
    • CTC CLUSTERS
    • CTC DETECTION
  • CANCER STEM CELLS (CSC)
    • TABLE 1: CATEGORIES OF STEM CELLS
    • TABLE 2: PRODUCT CATEGORIES
  • CIRCULATING TUMOR CELLS - POTENTIAL USES
    • TABLE 3: KEY FACTORS OF CTC'S
    • What Are Circulating Tumor Cells?
    • Biology and Characteristics of CTCs
      • TABLE 4: CIRCULATING TUMOR CELLS - FEATURES
  • PROLIFERATIVE ACTIVITY
  • EPITHELIAL MARKER GENES ON CIRCULATING TUMOR CELLS
    • CTCs as Biomarkers
    • Biomarker Qualification Program
    • Epithelial to Mesenchymal Transition
  • CIRCULATING TUMOR CELLS AND STEM CELL-LIKE PHENOTYPE
  • CTCS AND PRIMARY TUMOR CELLS: COMPARISON
  • METASTASIS
    • The Metastatic Process
  • FUTURE DIRECTIONS
    • TABLE 5: METASTATIC CASCADE
  • METASTATIC DEVELOPMENT IN CANCER PATIENTS
  • CIRCULATING TUMOR CELL MIGRATION
  • IMPORTANT MARKERS OF DISTANT METASTASIS
  • CIRCULATING TUMOR CELL DETECTION
    • TABLE 6: EPCAM-BASED ASSAYS
  • CHALLENGES FOR DETECTION
  • THE CLINICAL APPLICATION OF CIRCULATING TUMOR DNA
  • CIRCULATING TUMOR CELLS AS PREDICTOR OF RESPONSE TO THERAPY
  • MEASUREMENT OF CTCS - APPLICATIONS
  • CONCLUSION
    • TABLE 7: CTC DETECTION - ADVANTAGES

CHAPTER 4 - INCIDENCE OF CANCER

  • WORLDWIDE GROWTH IN THE INCIDENCE OF CANCER
    • TABLE 8: CANCER - KEY FACTS
  • CAUSES OF CANCER
    • TABLE 9: CANCER CAUSES
  • RISK FACTORS FOR CANCERS
  • BURDEN OF CANCER
  • AVOIDING RISK FACTORS
    • TABLE 10: CANCER CAUSING FACTORS
    • Prevention Strategies
  • EARLY DETECTION
    • Early Diagnosis
    • Screening
      • TABLE 11: CANCER SCREENING METHODS
  • TREATMENT
    • Treatment of Early-Detectable Cancers
    • Treatment of Other Cancers with Potential for Cure
  • PALLIATIVE CARE
    • Palliative Care Strategies
  • WORLD HEALTH ORGANIZATION RESPONSE
    • TABLE 12: NONCOMMUNICABLE DISEASES ACTION PLAN
  • WORLD CANCER STATISTICS
    • TABLE 13: GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS)
    • FIGURE 1: GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS)
    • TABLE 14: ESTIMATED GLOBAL CANCER INCIDENCE, 2008 (THOUSANDS)
  • CANCER AND THE GLOBAL IMPACT
    • Prevalence
    • Global Patterns
  • THE FUTURE OF CANCER
    • TABLE 15: INCREASE IN CANCER BURDEN - FACTORS
    • Common Types of Cancer
      • TABLE 16: THE MAIN TYPES OF CANCER AND ASSOCIATED MORTALITY
      • TABLE 17: GENERAL GLOBAL CANCER INCIDENCE BY TYPE
      • TABLE 18: GLOBAL INCIDENCE OF CANCER BY TYPE, 2008 (THOUSANDS/%)
    • Global Incidence in Men
      • TABLE 19: CANCER INCIDENCE IN MEN, 2008 (THOUSANDS/%)
    • Global Incidence in Women
      • TABLE 20: CANCER INCIDENCE IN WOMEN, 2008 (THOUSANDS/%)
    • Developed Countries
      • TABLE 21: GLOBAL INCIDENCE OF CANCER IN DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000, 2008
    • Men
      • TABLE 22: GLOBAL INCIDENCE OF CANCER IN MEN - DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008
    • Incidence in Women
      • TABLE 23: GLOBAL INCIDENCE OF CANCER IN WOMEN - DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008
  • UNITED STATES CANCER INCIDENCE
    • TABLE 24: UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, 2013
    • FIGURE 2: UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, 2013
  • BREAST CANCER
    • TABLE 25: GLOBAL BREAST CANCER FACTS
    • TABLE 26: BREAST CANCER IN THE UNITED STATES
  • COLORECTAL CANCER
    • TABLE 27: TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL CANCER IN MEN, 2008
    • TABLE 28: TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL CANCER IN WOMEN, 2008
    • U.S. Incidence
      • TABLE 29: UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, 2013
      • FIGURE 3: UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, 2013
  • PROSTATE CANCER
    • TABLE 30: TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF PROSTATE CANCER, 2008
    • Westernization Trends
      • TABLE 31: PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)
      • FIGURE 4: PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)
    • Prostate Cancer Mortality
      • TABLE 32: GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008
      • FIGURE 5: GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008
    • Prostate Cancer a Burden Globally
      • TABLE 33: GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, 2008-2030 (NUMBER)
      • FIGURE 6: GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER 2008-2030 (NUMBER)
    • Prostate Cancer and the U.S.
      • TABLE 34: PROSTATE CANCER CASES AND DEATHS IN THE U.S. 2008-2011 (NUMBER)
      • FIGURE 7: PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008-2011 (NUMBER)
      • TABLE 35: ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030 (NUMBER)
      • FIGURE 8: ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030 (NUMBER)
      • TABLE 36: PROSTATE CANCER INCIDENCE RATES IN THE U.S. BY RACE, 2005-2009 (PER 100,000 MEN)
      • TABLE 37: ESTIMATED PROSTATE CANCER CASES IN THE U S., 2020 AND 2030 (NUMBER)
      • FIGURE 9: ESTIMATED PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030 (NUMBER)
    • Prostate Cancer Mortality Rates in the U.S.
      • TABLE 38: MORTALITY RATES BY RACE IN U.S., 2005-2009
    • Prostate Cancer in Canada
      • TABLE 39: ESTIMATED PROSTATE CANCER IN CANADA, 2012 (NUMBER)
    • Prostate Cancer in Europe
      • TABLE 40: EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION, 2008
      • FIGURE 10: EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008
    • Prostate Cancer in the United Kingdom
      • TABLE 41: PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000 POPULATION)
      • FIGURE 11: PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000 POPULATION)
    • Prostate Cancer in Asia
  • CONCLUSIONS

CHAPTER 5 - TECHNOLOGIES

  • FINDING CIRCULATING TUMOR CELLS
    • TABLE 42: POTENTIAL APPLICATIONS OF CTC-BASED DIAGNOSTICS
  • CURRENT CTC DETECTION AND ISOLATION METHODS
  • NEW TECHNOLOGIES FOR THE DETECTION
  • CANCER PROGNOSIS
    • Carcinoma - CTC and the Metastatic Cascade
    • How many CTCs?
    • The Biological Characteristics of CTC
      • TABLE 43: CLINICAL RELEVANCE OF CTC
    • Cancer Dissemination
  • CTC DETECTION TECHNIQUES - REQUIREMENTS
    • TABLE 44: CTC ENRICHMENT METHODS
  • ENRICHMENT METHODS
    • TABLE 45: TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ENRICHMENT
    • Morphology-Based Enrichment Methods
      • Cell Separation Based on Density Gradient Centrifugation
      • Size-Based Cell Enrichment by Filtration
      • Immunomagnetic Separation Techniques
      • The RosetteSep-Applied Imaging Rare Event (RARE) Method
      • MagSweeper
  • DETECTION METHODS
    • TABLE 46: TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ANALYSIS
    • Immunocytochemical Approaches
    • Fiber-Optic Array Scanning Technology
    • Laser Scanning Cytometer
    • Multiphoton Intravital Flow Cytometry
  • COMBINED ENRICHMENT AND DETECTION METHODS
    • TABLE 47: ENUMERATION TECHNIQUES
    • CellSearch System
    • Microfluidic Devices
    • Microfluidic Chips
    • EPISPOT
    • AdnaTest
    • TelomeScan
    • CTC Chip
      • TABLE 48: FUNCTIONAL ASSAYS
  • NUCLEIC ACID-BASED METHODS
    • Limitations
    • Flow Cytometry
    • Image-Based Approaches
    • Reverse-Transcriptase PCR
  • CLINICAL TESTING
    • CTC Analysis in Cancer Patients
    • CTC Analysis in Patients with Metastatic Disease
  • SUMMARY
    • TABLE 49: KEY FACTS ABOUT CIRCULATING TUMOR CELLS
  • NEW EMERGING TECHNOLOGIES
    • TABLE 50: MICRO-COUNT FEATURES A NEW TECHNOLOGY
    • Herringbone-Chip (HB-Chip)
    • Future Directions

CHAPTER 6 - CIRCULATING TUMOR CELLS AND CANCER DIAGNOSTICS

  • TABLE 51: CTC ASSAY PRE-ANALYTICAL VALIDATION CONSIDERATIONS
  • TABLE 52: CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS
  • TABLE 53: CTC ASSAY POST-ANALYTICAL VALIDATION CONSIDERATIONS
  • USE OF CTC'S FOR DIAGNOSIS
    • TABLE 54: CURRENT ENRICHMENT ASSAYS FOR CTCS
    • TABLE 55: CTC ENUMERATION ASSAYS
  • CURRENT METHODS AND APPLICATIONS
    • CTC Chip
      • TABLE 56: CHARACTERIZATION ASSAYS FOR CTCS
    • IVD Diagnostics
      • TABLE 57: KEY FEATURES-IVD CTC TESTS
      • TABLE 58: TUMOR TYPES: PROJECTED NEW CASES AND ESTIMATED DEATHS, 2010
      • FIGURE 12: TUMOR TYPES - PROJECTED NEW CASES AND ESTIMATED DEATHS, 2010
    • IVDiagnostics Customized Aptamer Selection Service
    • IVDiagnostics CTC Capture
    • IVDiagnostics CTC Human Genetics
    • Biocept
  • CIRCULATING TUMOR CELLS IN PROSTATE CANCER: CASE STUDIES
    • TABLE 59: PROSTATE CANCER DIAGNOSIS AND ROLE OF CTC'S
  • CTC IN COMPANION DIAGNOSTICS
    • TABLE 60: CURRENT DIAGNOSTIC METHODS
    • ApoCell
      • TABLE 61: APOSTREAM KEY FEATURES
    • ApoStream CTC Imaging
    • Clarient Launches Biocept's OncoCEE-BR Test
    • Canopus Bioscience
      • TABLE 62: CANOPUS BIOSCIENCE TECHNOLOGY - BENEFITS
    • Ikonisys
      • TABLE 63: CELLOPTICS' CANCER APPLICATION
    • Technique
      • TABLE 64: CELLOPTICS' KEY FEATURES - ENRICHMENT
      • TABLE 65: CELLOPTICS' KEY FEATURES - LABELING
      • TABLE 66: CELLOPTICS' KEY FEATURES - DETECTION
    • RAREcells Diagnostics
      • TABLE 67: ISET TEST - SPECIFICATIONS
  • NEWER TECHNOLOGIES IN DEVELOPMENT
    • OriGene Technologies
      • Protein Microarray and Its Application
    • Viator Technologies
      • Photoacoustic Detection and Capture of CTCs
    • Micro Technologies
      • Interrogate Signaling in Single Cells
    • NanoVelcro
      • Embedded Microchips
  • MOLECULAR ANALYSES OF CTC
    • The Ephesia Magnetic Arrays Technology
    • New "Biopsy in a Blood Test"
  • CONCLUSIONS

CHAPTER 7 - CTCS IN CLINICAL TRIALS

  • CTC DIAGNOSTICS
    • CIRCULATING TUMOR CELL TECHNOLOGY
    • POTENTIAL THERAPEUTIC USES OF CIRCULATING TUMOR CELLS
    • CHALLENGES IN THE DETECTION OF CIRCULATING TUMOR CELLS
    • CTC'S AS CLINICAL BIOMARKERS
    • PCR-BASED MARKERS
      • Carcinoma Cells
    • CIRCULATING TUMOR CELLS IN CANCER - CURRENT STATUS
      • Breast Cancer
      • STIC CTC METABREAST (France)
      • SWOG 0500 (USA)
      • CirCe01 (France)
      • Treat CTC (Europe)
      • DETECT III (Germany)
    • PROGNOSTIC AND PREDICTIVE VALUE OF CIRCULATING TUMOR CELLS (CTC'S)
      • Breast Cancer
      • Pancreatic Cancer
      • Lung Cancer
    • CTC'S IN CLINICAL CANCER MANAGEMENT
      • TABLE 68: CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT
      • Clinical Impact of CTCs
    • EXISTING TECHNOLOGIES IN CLINICAL TRIALS
      • Cell Search and AdnaTest - Comparision
      • Size- and Biomechanical Properties-Based Isolation
    • CLINICAL STUDIES USING CELLSEARCH TECHNOLOGY
      • TABLE 69: CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT
  • APPROVALS
  • RECENT STUDIES
    • Tumor Cell (CTC) Enumeration Using Cellsearch
  • CELLSEARCH IN CHINA
    • VERIDEX AND MASSACHUSETTS GENERAL HOSPITAL COLLABORATION
    • POSSIBLE USE OF CTC'S AND DTC'S AS NEW BIOMARKERS
      • EPISPOT
    • CLINCIAL APPLICATIONS
      • TABLE 70: EPISPOT: CLINICAL TRIALS FOR DETECTION OF CTC'S
      • Descriptions of Clinical Trials
        • NCT01402154 Trial
        • NCT01558349 Trial
        • NCT01596790 Trial
        • TABLE 71: OUTCOME MEASUREMENTS NCT01596790 TRIAL
      • ApoCell
        • ApoCell and Transgenomic Present Results of Lung Cancer Research Study
        • ApoCell's CTC Capture Technology Detects and Recovers Deadly Liver Cancer Cells
        • Nektar's Ongoing Phase 3 BEACON Study
  • APPLICATIONS
    • Application of iCTC Detection and Culture in Personalized Cancer Management
      • Stony Brook University Medical Center
    • Microfluidic Sorting of Blood Cells for Cellular and Molecular Analysis
    • Cancer Sample Preparation with Micromachined Magnetic Sifter and Nanoparticles
      • Stanford Center for Magnetic Nanotechnology
    • The Scripps Research Institute: The Fluid Phase of Solid Tumors
    • ApoCell - Utilization of Dielectrophoresis for Antigen-Independent CTC Capture Allows for Detection of Heterogeneous Tumor Cell Populations
  • APPLICATION OF CTC TECHNOLOGIES TO CLINICAL TESTING
  • CTC TECHNOLOGIES FOR CLINICAL DEVELOPMENT
    • Practical Application
      • TABLE 72: CTC ASSAY CLINICAL READINESS EVALUATION
      • TABLE 73: CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS
  • STANDARD RECOMMENDATIONS
    • Specificity of a CTC Assay
    • Clinical Trial Design Considerations
      • TABLE 74: CTC QUALIFICATION STUDIES
    • SWOG S0500 Trial
    • Study Strategy and Process
  • CTC NUMBER AS A PROGNOSTIC BIOMARKER
    • Breast Cancer
    • Metastatic Castrate-resistant Prostate Cancer
    • Colorectal Cancer
    • Lung Cancer
  • PROGNOSTIC STUDIES
  • CTC'S AS A SURROGATE RESPONSE BIOMARKER
  • CTC'S AS A REAL-TIME BIOPSY
  • CTC CHIP TECHNOLOGY AND EGFR MUTATION ANALYSIS
  • CTC CHARACTERIZATION AFTER ENRICHMENT USING THE CELLSEARCH PLATFORM
  • FINAL REMARKS

CHAPTER 8 - CIRCULATING TUMOR CELL MARKET

  • THE INVASIVE CANCER!
    • TABLE 75: GLOBAL CANCER INCIDENCE - ESTIMATES, 2008-2030 (MILLIONS)
    • FIGURE 13: GLOBAL CANCER INCIDENCE - ESTIMATES, 2008-2030 (MILLIONS)
  • CANCER SURVIVAL
    • TABLE 76: GLOBAL CANCER SURVIVORS, 2008 (MILLIONS)
    • FIGURE 14: GLOBAL CANCER SURVIVORS 2008 (MILLIONS)
    • TABLE 77: UNITED STATES CANCER SURVIVORS, 2008-2022 (MILLIONS)
    • TABLE 78: MALE CANCER SURVIVORS (%)
    • TABLE 79: FEMALE CANCER SURVIVORS (%)
  • GLOBAL ANNUAL ONCOLOGY MARKET
    • CANCER THERAPY
      • TABLE 80: MAJOR PLAYERS
      • TABLE 81: GLOBAL CANCER DRUG MARKET SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
      • FIGURE 15 GLOBAL CANCER DRUG MARKET SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • AGING AND CANCER
    • CANCER DRUG PIPELINE
      • TABLE 82: DRUGS APPROVED IN 2013
  • CANCER COSTS IN THE U.S.
    • TABLE 83: CANCER FORECAST IN U.S., 2020 - KEY FACTS
    • TABLE 84: CANCER CARE COST IN U.S., 2010 AND 2020 ($ BILLIONS)
  • BREAST CANCER
    • Treatment and Survival
    • Common Side Effects of Treatment
  • COLON AND RECTUM
    • Treatment and Survival
    • Common Side Effects of Treatment
  • PROSTATE
    • Treatment and Survival
    • Common Side Effects of Treatment
  • CHEMOTHERAPY MARKET
    • CANCER TESTING MARKET
      • TABLE 85: GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST THROUGH 2018 ($ MILLIONS)
      • FIGURE 16 GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST 2012-2018 ($ MILLIONS)
      • TABLE 86: CANCER TESTING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
      • FIGURE 17: CANCER TESTING MARKET AND FORECAST, 2012-2018 ($ MILLIONS)
      • TABLE 87: KEY PLAYERS
    • IVD Market in China
  • CURRENT CANCER DIAGNOSTIC TESTS
    • Cancer Testing in Developing Nations
    • New Opportunities
      • TABLE 88: SIGNIFICANT DEVELOPMENTS IN CANCER FOLLOW-UP
  • A UNIVERSAL TUMOR TEST- IS IT POSSIBLE?
    • TABLE 89: CANCER TESTS AND LIMITATIONS - THE CASE AGAINST DEVELOPMENT OF A UNIVERSAL TEST
  • CANCER BIOMARKER TESTING MARKET
    • TABLE 90: GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 18: GLOBAL BIOMARKER MARKET AND FORECAST, 2012-2018 ($ MILLIONS)
    • TABLE 91: THE KEY PLAYERS
    • TABLE 92: U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 19: U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, 2012-2018 ($ MILLIONS)
  • MOLECULAR DIAGNOSTICS
    • TABLE 93: MOLECULAR DIAGNOSTICS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 20: MOLECULAR DIAGNOSTICS MARKET AND FORECAST, 2012-2018 ($ MILLIONS)
  • CANCER BIOMARKER TESTS
  • CANCER DISEASE MANAGEMENT
  • PERSONALIZED CANCER TESTING
    • Cancer Testing Competitors
  • CIRCULATING TUMOR CELL MARKET - A NEW APPROACH
    • TABLE 94: CTC'S - DIFFERENTIATING FEATURES
    • CTCs Advantages
  • THE CLINICAL DIAGNOSTICS MARKET
    • Market Opportunities
      • TABLE 95: STEM CELL MARKET OVERVIEW
      • TABLE 96: KEY COMPANIES SELLING STEM CELL RESEARCH PRODUCTS
    • CTC Testing
      • TABLE 97: CTC COMPANIES WITH PROMISING PRODUCTS
    • CellSearch CTC test
      • TABLE 98: CLINICAL USE OF CELLSEARCH SYSTEM
    • AdnaTest
  • CURRENT STATUS OF THE MARKET
    • TABLE 99: PRICING (DOLLARS)
    • TABLE 100: CELLSEARCH KIT
    • Updated Coding and Payment for Circulating Tumor Cell Testing
    • Global Market for Circulating Cancer Cells (CTCs)
      • TABLE 101: GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 21: GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS)
      • TABLE 102: GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 22: GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS)
      • TABLE 103: GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 23: GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER - SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS)
      • TABLE 104: GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS)
      • FIGURE 24: GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER -SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS)
    • United States Market for Circulating Cancer Cells (CTCs)
      • TABLE 105: U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
      • FIGURE 25: U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • TIMELINE
    • TABLE 106: U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION, SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • FIGURE 26: U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION SALES AND FORECAST, 2012-2018 ($ MILLIONS)
    • Europe - Market for Circulating Cancer Cells (CTCs)
      • TABLE 107: EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
      • FIGURE 27: EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, 2012-2018 ($ MILLIONS)
      • TABLE 108: EUROPEAN CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • Rest of World Market for Circulating Cancer Cells (CTCs)
      • TABLE 109: REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
      • FIGURE 28: REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, 2012-2018 ($ MILLIONS)
    • Canada
      • TABLE 110: REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
      • FIGURE 29: REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, 2012-2018 ($ MILLIONS)
  • ASIA-PACIFIC SOLID TUMORS MARKET
  • FUTURE AND NEXT STEPS

CHAPTER 9 - PATENTS

  • TABLE 111: CIRCULATING TUMOR CELL ASSAY CHARACTERISTICS
  • KEY PATENTS
    • TABLE 112: CTC PATENTS
  • VERIDEX
    • EpCAM Based Enrichment Using Magnetic Beads
  • MAGSWEEPER
    • EpCAM Based Magnetic Beads
  • SCRIPPS RESEARCH INSTITUTE (EPIC SCIENCES)
    • HD-CTC Technology
  • CELLPOINT DIAGNOSTICS
  • ON-Q-ITY
  • BIOFLUIDICA
  • ADNAGEN
    • Multiple Antibodies on Magnetic Beads
  • FILTINI
    • 3D Parylene Membrane Filter for Isolation of CTC
  • IKONISYS
  • AVIVA BIOSCIENCES
    • Methods, Compositions, and Automated Systems for Separating Rare Cells
      • TABLE 113: KEY PATENTS BY AVIVA BIOSCIENCES
  • HARVARD UNIVERSITY - MEHMET TONER, PHD
    • Microposts Coated with EpCAM
  • CELLECTIVE DX
    • Materal Displacement Obstacle Chip
  • JOHNS HOPKINS UNIVERSITY
    • Antibody-Coated Microfluidic Chip and Quantum Dots-Based Imaging
  • MEDICAL DISCOVERY PARTNERS
    • RBC Agglutination Followed by Filtration
  • CYNVENIO BIOSYSTEMS
    • Microfluidic Sheath Flow for Cell Isolation
  • SCREENCELL
  • BIOCEPT
    • Recovery of Rare Cells Using a Microchannel Apparatus with Patterned Posts
  • CANOPUS BIOSCIENCE
    • Enrichment Technology Is Now Protected by Key Patents
  • ADVANCED CELL DIAGNOSTICS

CHAPTER 10 - SELECTED COMPANY PROFILES

  • COMPANIES
    • KEY PLAYERS
      • TABLE 114: COMMERCIAL CIRCULATING TUMOR CELL TECHNOLOGY PLATFORMS
  • KEY COMPANY PROFILES
  • ADNAGEN
  • ADVANCED CELL DIAGNOSTICS
  • APOCELL
  • AVIVA BIOSCIENCES
  • BIOCEP LTD.
  • BIOCEPT INC.
  • BIOFLUIDICA MICROTECHNOLOGIES LLC
  • CANOPUS BIOSCIENCES
  • CELLTRAFIX INC.
  • CELULA
  • CLEARBRIDGE BIOMEDICS
  • CREATV MICROTECH INC
  • CYNVENIO BIOSYSTEMS, INC.
  • EPIC BIOSCIENCES
  • FILTINI INC.
  • FLUXION BIOSCIENCES
  • GREINER BIO-ONE GMBH
  • IKONISYS INC.
  • IVDIAGNOSTICS INC.
  • JANSSEN DIAGNOSTICS
  • MILTENYI BIOTECH
  • NANOSTRING TECHNOLOGIES INC.
  • NATURAL NANO INC.
  • ONCO VISTA
  • ON-Q-ITY
  • RARECELLS
  • SCREENCELL
  • SILICON BIOSYSTEMS USA
  • STEMCELL TECHNOLOGIES
  • SYNERGEX CORPORATION
  • SYSMEX CORPORATION
  • VERIDEX, LLC
  • VITATEX INC.

CHAPTER 11 - REFERENCES

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING TUMOR CELL TECHNOLOGY, THROUGH 2018 ($ MILLIONS)
    • TABLE 1: CATEGORIES OF STEM CELLS
    • TABLE 2: PRODUCT CATEGORIES
    • TABLE 3: KEY FACTORS OF CTC'S
    • TABLE 4: CIRCULATING TUMOR CELLS - FEATURES
    • TABLE 5: METASTATIC CASCADE
    • TABLE 6: EPCAM-BASED ASSAYS
    • TABLE 7: CTC DETECTION - ADVANTAGES
    • TABLE 8: CANCER - KEY FACTS
    • TABLE 9: CANCER CAUSES
    • TABLE 10: CANCER CAUSING FACTORS
    • TABLE 11: CANCER SCREENING METHODS
    • TABLE 12: NONCOMMUNICABLE DISEASES ACTION PLAN
    • TABLE 13: GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS)
    • TABLE 14: ESTIMATED GLOBAL CANCER INCIDENCE, 2008 (THOUSANDS)
    • TABLE 15: INCREASE IN CANCER BURDEN - FACTORS
    • TABLE 16: THE MAIN TYPES OF CANCER AND ASSOCIATED MORTALITY
    • TABLE 17: GENERAL GLOBAL CANCER INCIDENCE BY TYPE
    • TABLE 18: GLOBAL INCIDENCE OF CANCER BY TYPE, 2008 (THOUSANDS/%)
    • TABLE 19: CANCER INCIDENCE IN MEN, 2008 (THOUSANDS/%)
    • TABLE 20: CANCER INCIDENCE IN WOMEN, 2008 (THOUSANDS/%)
    • TABLE 21: GLOBAL INCIDENCE OF CANCER IN DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000, 2008
    • TABLE 22: GLOBAL INCIDENCE OF CANCER IN MEN - DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008
    • TABLE 23: GLOBAL INCIDENCE OF CANCER IN WOMEN - DEVELOPED COUNTRIES AGE-STANDARDIZED RATE PER 100,000 (WORLD), 2008
    • TABLE 24: UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, 2013
    • TABLE 25: GLOBAL BREAST CANCER FACTS
    • TABLE 26: BREAST CANCER IN THE UNITED STATES
    • TABLE 27: TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL CANCER IN MEN, 2008
    • TABLE 28: TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF COLORECTAL CANCER IN WOMEN, 2008
    • TABLE 29: UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, 2013
    • TABLE 30: TOP 20 COUNTRIES WITH THE HIGHEST INCIDENCE OF PROSTATE CANCER, 2008
    • TABLE 31: PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)
    • TABLE 32: GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008
    • TABLE 33: GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER, 2008-2030 (NUMBER)
    • TABLE 34: PROSTATE CANCER CASES AND DEATHS IN THE U.S. 2008-2011 (NUMBER)
    • TABLE 35: ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030 (NUMBER)
    • TABLE 36: PROSTATE CANCER INCIDENCE RATES IN THE U.S. BY RACE, 2005-2009 (PER 100,000 MEN)
    • TABLE 37: ESTIMATED PROSTATE CANCER CASES IN THE U S., 2020 AND 2030 (NUMBER)
    • TABLE 38: MORTALITY RATES BY RACE IN U.S., 2005-2009
    • TABLE 39: ESTIMATED PROSTATE CANCER IN CANADA, 2012 (NUMBER)
    • TABLE 40: EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATION, 2008
    • TABLE 41: PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000 POPULATION)
    • TABLE 42: POTENTIAL APPLICATIONS OF CTC-BASED DIAGNOSTICS
    • TABLE 43: CLINICAL RELEVANCE OF CTC
    • TABLE 44: CTC ENRICHMENT METHODS
    • TABLE 45: TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ENRICHMENT
    • TABLE 46: TECHNIQUES USED FOR CIRCULATING TUMOR CELL (CTC) ANALYSIS
    • TABLE 47: ENUMERATION TECHNIQUES
    • TABLE 48: FUNCTIONAL ASSAYS
    • TABLE 49: KEY FACTS ABOUT CIRCULATING TUMOR CELLS
    • TABLE 50: MICRO-COUNT FEATURES A NEW TECHNOLOGY
    • TABLE 51: CTC ASSAY PRE-ANALYTICAL VALIDATION CONSIDERATIONS
    • TABLE 52: CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS
    • TABLE 53: CTC ASSAY POST-ANALYTICAL VALIDATION CONSIDERATIONS
    • TABLE 54: CURRENT ENRICHMENT ASSAYS FOR CTCS
    • TABLE 55: CTC ENUMERATION ASSAYS
    • TABLE 56: CHARACTERIZATION ASSAYS FOR CTCS
    • TABLE 57: KEY FEATURES-IVD CTC TESTS
    • TABLE 58: TUMOR TYPES: PROJECTED NEW CASES AND ESTIMATED DEATHS, 2010
    • TABLE 59: PROSTATE CANCER DIAGNOSIS AND ROLE OF CTC'S
    • TABLE 60: CURRENT DIAGNOSTIC METHODS
    • TABLE 61: APOSTREAM KEY FEATURES
    • TABLE 62: CANOPUS BIOSCIENCE TECHNOLOGY - BENEFITS
    • TABLE 63: CELLOPTICS' CANCER APPLICATION
    • TABLE 64: CELLOPTICS' KEY FEATURES - ENRICHMENT
    • TABLE 65: CELLOPTICS' KEY FEATURES - LABELING
    • TABLE 66: CELLOPTICS' KEY FEATURES - DETECTION
    • TABLE 67: ISET TEST - SPECIFICATIONS
    • TABLE 68: CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT
    • TABLE 69: CTC TECHNOLOGIES FOR CLINICAL MANAGEMENT
    • TABLE 70: EPISPOT: CLINICAL TRIALS FOR DETECTION OF CTC'S
    • TABLE 71: OUTCOME MEASUREMENTS NCT01596790 TRIAL
    • TABLE 72: CTC ASSAY CLINICAL READINESS EVALUATION
    • TABLE 73: CTC ASSAY ANALYTICAL VALIDATION CONSIDERATIONS
    • TABLE 74: CTC QUALIFICATION STUDIES
    • TABLE 75: GLOBAL CANCER INCIDENCE - ESTIMATES, 2008-2030 (MILLIONS)
    • TABLE 76: GLOBAL CANCER SURVIVORS, 2008 (MILLIONS)
    • TABLE 77: UNITED STATES CANCER SURVIVORS, 2008-2022 (MILLIONS)
    • TABLE 78: MALE CANCER SURVIVORS (%)
    • TABLE 79: FEMALE CANCER SURVIVORS (%)
    • TABLE 80: MAJOR PLAYERS
    • TABLE 81: GLOBAL CANCER DRUG MARKET SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 82: DRUGS APPROVED IN 2013
    • TABLE 83: CANCER FORECAST IN U.S., 2020 - KEY FACTS
    • TABLE 84: CANCER CARE COST IN U.S., 2010 AND 2020 ($ BILLIONS)
    • TABLE 85: GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST THROUGH 2018 ($ MILLIONS)
    • TABLE 86: CANCER TESTING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 87: KEY PLAYERS
    • TABLE 88: SIGNIFICANT DEVELOPMENTS IN CANCER FOLLOW-UP
    • TABLE 89: CANCER TESTS AND LIMITATIONS - THE CASE AGAINST DEVELOPMENT OF A UNIVERSAL TEST
    • TABLE 90: GLOBAL BIOMARKER MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 91: THE KEY PLAYERS
    • TABLE 92: U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 93: MOLECULAR DIAGNOSTICS MARKET AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 94: CTC'S - DIFFERENTIATING FEATURES
    • TABLE 95: STEM CELL MARKET OVERVIEW
    • TABLE 96: KEY COMPANIES SELLING STEM CELL RESEARCH PRODUCTS
    • TABLE 97: CTC COMPANIES WITH PROMISING PRODUCTS
    • TABLE 98: CLINICAL USE OF CELLSEARCH SYSTEM
    • TABLE 99: PRICING (DOLLARS)
    • TABLE 100: CELLSEARCH KIT
    • TABLE 101: GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 102: GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 103: GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 104: GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER - SALES AND FORECAST BY REGION, THROUGH 2018 ($ MILLIONS)
    • TABLE 105: U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 106: U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION, SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 107: EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 108: EUROPEAN CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 109: REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 110: REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, THROUGH 2018 ($ MILLIONS)
    • TABLE 111: CIRCULATING TUMOR CELL ASSAY CHARACTERISTICS
    • TABLE 112: CTC PATENTS
    • TABLE 113: KEY PATENTS BY AVIVA BIOSCIENCES
    • TABLE 114: COMMERCIAL CIRCULATING TUMOR CELL TECHNOLOGY PLATFORMS

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET SALES AND FORECAST FOR CIRCULATING TUMOR CELL TECHNOLOGY, 2012-2018 ($ MILLIONS)
    • FIGURE 1: GLOBAL CANCER INCIDENCE ESTIMATES, 2008 AND 2030 (MILLIONS)
    • FIGURE 2: UNITED STATES - COMMON TYPE OF CANCER ESTIMATES, 2013
    • FIGURE 3: UNITED STATES - COLORECTAL CANCER INCIDENCE ESTIMATES, 2013
    • FIGURE 4: PROSTATE CANCER INCIDENCE AND MORTALITY WORLDWIDE, 2008 (THOUSANDS)
    • FIGURE 5: GLOBAL ESTIMATED PROSTATE CANCER DEATHS AND AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008
    • FIGURE 6: GLOBAL ESTIMATED NEW CASES OF PROSTATE CANCER 2008-2030 (NUMBER)
    • FIGURE 7: PROSTATE CANCER CASES AND DEATHS IN THE U.S., 2008-2011 (NUMBER)
    • FIGURE 8: ESTIMATED NEW CASES OF PROSTATE CANCER IN THE U.S., 2012-2030 (NUMBER)
    • FIGURE 9: ESTIMATED PROSTATE CANCER CASES IN THE U.S., 2020 AND 2030 (NUMBER)
    • FIGURE 10: EUROPEAN (EU27 COUNTRIES) ESTIMATED PROSTATE CANCER MORTALITY - AGE-STANDARDIZED MORTALITY RATES PER 100,000 POPULATIONS, 2008
    • FIGURE 11: PROSTATE CANCER DEATHS IN THE U.K., 2010 (RATE PER 100,000 POPULATION)
    • FIGURE 12: TUMOR TYPES - PROJECTED NEW CASES AND ESTIMATED DEATHS, 2010
    • FIGURE 13: GLOBAL CANCER INCIDENCE - ESTIMATES, 2008-2030 (MILLIONS)
    • FIGURE 14: GLOBAL CANCER SURVIVORS 2008 (MILLIONS)
    • FIGURE 15: GLOBAL CANCER DRUG MARKET SALES AND FORECAST, 2012-2018 ($ MILLIONS)
    • FIGURE 16: GLOBAL IN VITRO DIAGNOSTICS MARKET SALES AND FORECAST 2012-2018 ($ MILLIONS)
    • FIGURE 17: CANCER TESTING MARKET AND FORECAST, 2012-2018 ($ MILLIONS)
    • FIGURE 18: GLOBAL BIOMARKER MARKET AND FORECAST, 2012-2018 ($ MILLIONS)
    • FIGURE 19: U.S. BIOMARKER CANCER TESTING MARKET AND FORECAST, 2012-2018 ($ MILLIONS)
    • FIGURE 20: MOLECULAR DIAGNOSTICS MARKET AND FORECAST, 2012-2018 ($ MILLIONS)
    • FIGURE 21: GLOBAL CIRCULATING TUMOR CELL TESTING MARKET SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS)
    • FIGURE 22: GLOBAL CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS)
    • FIGURE 23: GLOBAL CIRCULATING TUMOR CELL MARKET FOR BREAST CANCER - SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS)
    • FIGURE 24: GLOBAL CIRCULATING TUMOR CELL MARKET FOR COLORECTAL CANCER -SALES AND FORECAST BY REGION, 2012-2018 ($ MILLIONS)
    • FIGURE 25: U.S. CIRCULATING TUMOR CELL MARKET FOR PROSTATE CANCER - SALES AND FORECAST, 2012-2018 ($ MILLIONS)
    • FIGURE 26: U.S. CIRCULATING TUMOR CELL MARKET - BY INDICATION SALES AND FORECAST, 2012-2018 ($ MILLIONS)
    • FIGURE 27: EUROPEAN CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, 2012-2018 ($ MILLIONS)
    • FIGURE 28: REST OF WORLD CIRCULATING TUMOR CELL MARKET SALES AND FORECAST, 2012-2018 ($ MILLIONS)
    • FIGURE 29: REST OF WORLD CIRCULATING TUMOR CELL MARKET BY CANCER TYPE - SALES AND FORECAST, 2012-2018 ($ MILLIONS)
Back to Top